

Joop A M J L Janssen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6875773/publications.pdf>

Version: 2024-02-01

148
papers

8,211
citations

44069

48
h-index

51608

86
g-index

151
all docs

151
docs citations

151
times ranked

8469
citing authors

#	ARTICLE	IF	CITATIONS
1	It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, S1-S12.	3.6	17
2	Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. <i>Cells</i> , 2021, 10, 383.	4.1	10
3	Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 645732.	2.8	2
4	Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7797.	4.1	88
5	Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4626-e4637.	3.6	2
6	Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1397-e1407.	3.6	3
7	Mechanisms of putative IGF-I receptor resistance in active acromegaly. <i>Growth Hormone and IGF Research</i> , 2020, 52, 101319.	1.1	8
8	Soluble Klotho: a possible predictor of quality of life in acromegaly patients. <i>Endocrine</i> , 2020, 69, 165-174.	2.3	10
9	New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations. <i>Cells</i> , 2020, 9, 862.	4.1	24
10	The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease. <i>Growth Hormone and IGF Research</i> , 2019, 48-49, 16-28.	1.1	8
11	IGF-I and the endocrinology of aging. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 5, 1-6.	1.4	5
12	Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. <i>Endocrine Reviews</i> , 2019, 40, 236-267.	20.1	117
13	How to Position Pasireotide LAR Treatment in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1978-1988.	3.6	32
14	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. <i>Endocrine</i> , 2019, 64, 673-684.	2.3	23
15	Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 20.	3.4	24
16	Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 915-924.	3.6	37
17	Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. <i>European Journal of Endocrinology</i> , 2019, 181, 173-183.	3.7	12
18	Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 586-595.	3.6	58

#	ARTICLE	IF	CITATIONS
19	Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins. <i>European Journal of Endocrinology</i> , 2018, 178, 153-161.	3.7	3
20	Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms. <i>Transplantation Direct</i> , 2018, 4, e350.	1.6	8
21	Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study. <i>European Journal of Endocrinology</i> , 2018, 178, 93-102.	3.7	42
22	Disagreement in normative <sc>IGF</sc> levels may lead to different clinical interpretations and <sc>GH</sc> dose adjustments in <sc>GH</sc> deficiency. <i>Clinical Endocrinology</i> , 2018, 88, 409-414.	2.4	8
23	The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. <i>European Journal of Endocrinology</i> , 2018, 178, 11-22.	3.7	41
24	Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. <i>European Journal of Endocrinology</i> , 2018, 179, 269-277.	3.7	38
25	Very long-term sequelae of craniopharyngioma. <i>European Journal of Endocrinology</i> , 2017, 176, 755-767.	3.7	76
26	Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3814-3821.	3.6	3
27	Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747). <i>Thyroid</i> , 2017, 27, 1458-1459.	4.5	10
28	Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. <i>Neuroendocrinology</i> , 2017, 105, 44-53.	2.5	24
29	Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up. <i>International Journal of Obesity</i> , 2017, 41, 210-216.	3.4	45
30	Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells. <i>Neuroendocrinology</i> , 2016, 103, 815-825.	2.5	11
31	Genomewide meta-analysis identifies loci associated with <sc>IGF</sc> and <sc>IGFBP</sc> levels with impact on age-related traits. <i>Aging Cell</i> , 2016, 15, 811-824.	6.7	83
32	Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. <i>Endocrine-Related Cancer</i> , 2016, 23, 727-737.	3.1	21
33	Impact of Physical Exercise on Endocrine Aging. <i>Frontiers of Hormone Research</i> , 2016, 47, 68-81.	1.0	30
34	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016, 76, 2288-2300.	0.9	117
35	What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?. <i>European Journal of Endocrinology</i> , 2016, 174, 663-667.	3.7	11
36	Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2016, 7, 167.	3.5	31

#	ARTICLE	IF	CITATIONS
37	Potency of Full- Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. PLoS ONE, 2016, 11, e0150453.	2.5	6
38	Absence or low IGF-1R expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection. Journal of Surgical Oncology, 2015, 111, 1047-1053.	1.7	5
39	An Early Diagnostic Tool for Diabetic Peripheral Neuropathy in Rats. PLoS ONE, 2015, 10, e0126892.	2.5	13
40	The Introduction of the IDS-iSYS Total IGF-1 Assay May Have Far-Reaching Consequences for Diagnosis and Treatment of GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 309-316.	3.6	19
41	Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults. European Journal of Endocrinology, 2015, 173, 119-127.	3.7	3
42	IFN- γ is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells. American Journal of Cancer Research, 2015, 5, 2035-46.	1.4	3
43	Diabetes Associated with Glucocorticoid Excess. Frontiers in Diabetes, 2014, , 22-33.	0.4	1
44	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocrine-Related Cancer, 2014, 21, 601-613.	3.1	25
45	Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3644-3652.	3.6	103
46	IGF-IR Targeted Therapy: Past, Present and Future. Frontiers in Endocrinology, 2014, 5, 224.	3.5	49
47	Insulin Analogs and Cancer: A Note of Caution. Frontiers in Endocrinology, 2014, 5, 79.	3.5	14
48	Insulin-Like Growth Factor-I Receptor Stimulating Activity is Associated with Dementia. Journal of Alzheimer's Disease, 2014, 42, 137-142.	2.6	25
49	In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life. Endocrine Connections, 2014, 3, 85-92.	1.9	12
50	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4942-4952.	3.6	81
51	Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling. Diabetes, 2013, 62, 2539-2544.	0.6	19
52	Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling. Molecular and Cellular Endocrinology, 2013, 365, 17-24.	3.2	9
53	IGF-I Bioactivity Might Reflect Different Aspects of Quality of Life Than Total IGF-I in GH-Deficient Patients During GH Treatment. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 761-768.	3.6	23
54	Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. Endocrine Connections, 2013, 2, 172-177.	1.9	11

#	ARTICLE	IF	CITATIONS
55	Circulating IgGs May Modulate IGF-I Receptor Stimulating Activity in a Subset of Patients With Graves' Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 769-776.	3.6	161
56	High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control. <i>Diabetes Care</i> , 2013, 36, 1619-1628.	8.6	309
57	Insulin and its analogues and their affinities for the IGF1 receptor. <i>Endocrine-Related Cancer</i> , 2012, 19, F63-F75.	3.1	83
58	High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men. <i>European Journal of Endocrinology</i> , 2012, 167, 111-117.	3.7	25
59	Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. <i>Diabetologia</i> , 2012, 55, 1186-1194.	6.3	14
60	Low circulating IGF-I bioactivity is associated with human longevity: Findings in centenariansâ€™ offspring. <i>Aging</i> , 2012, 4, 580-589.	3.1	78
61	Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 372-7.	3.3	1
62	Effect of Intensive Insulin Therapy on the Somatotrophic Axis of Critically Ill Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2558-2566.	3.6	19
63	IGF-I Bioactivity Better Reflects Growth Hormone Deficiency than Total IGF-I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2248-2254.	3.6	19
64	Insulin-Like Growth Factor I: Pros and Cons of a Bioassay. <i>Hormone Research in Paediatrics</i> , 2011, 76, 106-110.	1.8	20
65	IGF-I Bioactivity in an Elderly Population: Relation to Insulin Sensitivity, Insulin Levels, and the Metabolic Syndrome. <i>Diabetes</i> , 2010, 59, 505-508.	0.6	35
66	Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 940-946.	0.7	6
67	Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. <i>Growth Hormone and IGF Research</i> , 2010, 20, 427-431.	1.1	21
68	P108 Effect of intensive insulin therapy on the somatotrophic axis in critically ill children. <i>Growth Hormone and IGF Research</i> , 2010, 20, S80.	1.1	0
69	Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. <i>European Journal of Endocrinology</i> , 2009, 160, 529-533.	3.7	110
70	Heterophilic antibodies may be a cause of falsely low total IGF1 levels. <i>European Journal of Endocrinology</i> , 2009, 161, 561-565.	3.7	19
71	Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E559-E566.	3.5	27
72	Advantages and disadvantages of GH/IGF-I combination treatment. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2009, 10, 157-162.	5.7	16

#	ARTICLE	IF	CITATIONS
73	Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3853-3859.	3.6	153
74	Normal Values of Circulating Insulin-Like Growth Factor-I Bioactivity in the Healthy Population: Comparison with Five Widely Used IGF-I Immunoassays. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2539-2545.	3.6	58
75	Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men Is Associated with Increased Mortality. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2515-2522.	3.6	78
76	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. Annals of Internal Medicine, 2008, 149, 461.	3.9	263
77	Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E697-E704.	3.5	64
78	Intravenous Glucose Administration in Fasting Rats Has Differential Effects on Acylated and Unacylated Ghrelin in the Portal and Systemic Circulation: A Comparison between Portal and Peripheral Concentrations in Anesthetized Rats. Endocrinology, 2007, 148, 5278-5287.	2.8	18
79	Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4598-4601.	3.6	146
80	Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes. Diabetes, 2007, 56, 1905-1912.	0.6	13
81	An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. European Journal of Endocrinology, 2007, 156, 83-90.	3.7	10
82	IGF-1 CA repeat variant and breast cancer risk in postmenopausal women. European Journal of Cancer, 2007, 43, 1718-1722.	2.8	14
83	The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men. Clinical Endocrinology, 2007, 66, 808-815.	2.4	35
84	Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. Molecular and Cellular Endocrinology, 2006, 251, 103-111.	3.2	73
85	The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. Clinical Endocrinology, 2006, 64, 203-208.	2.4	5
86	An Insulin-Like Growth Factor-I Promoter Polymorphism Is Associated With Increased Mortality in Subjects With Myocardial Infarction in an Elderly Caucasian Population. American Journal of Cardiology, 2006, 97, 1274-1276.	1.6	18
87	Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. European Journal of Endocrinology, 2006, 155, 293-296.	3.7	18
88	Retinal Vessel Diameters and Risk of Impaired Fasting Glucose or Diabetes. Diabetes, 2006, 55, 506-510.	0.6	114
89	An IGF-I Gene Polymorphism Modifies the Risk of Diabetic Retinopathy. Diabetes, 2006, 55, 2387-2391.	0.6	24
90	IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. European Journal of Endocrinology, 2006, 155, 751-756.	3.7	13

#	ARTICLE	IF	CITATIONS
91	An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose tolerance. <i>European Journal of Endocrinology</i> , 2006, 154, 715-721.	3.7	10
92	The α -Adducin Gene Is Associated With Macrovascular Complications and Mortality in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2006, 55, 2922-2927.	0.6	17
93	The α -bio-assay TM quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. <i>European Journal of Endocrinology</i> , 2005, 152, 217-224.	3.7	36
94	A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 289, E75-E81.	3.5	98
95	Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. <i>European Journal of Endocrinology</i> , 2005, 153, 67-71.	3.7	42
96	A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy. <i>Heart</i> , 2005, 91, 239-240.	2.9	23
97	Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6480-6489.	3.6	91
98	A Polymorphism in Type I Deiodinase Is Associated with Circulating Free Insulin-Like Growth Factor I Levels and Body Composition in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 256-263.	3.6	50
99	Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. <i>Lancet</i> , The, 2005, 365, 1644-1646.	13.7	214
100	Ghrelin Stimulates, Whereas Des-Octanoyl Ghrelin Inhibits, Glucose Output by Primary Hepatocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1055-1060.	3.6	269
101	Circulating Free Insulin-Like Growth Factor (IGF)-I, Total IGF-I, and IGF Binding Protein-3 Levels Do Not Predict the Future Risk to Develop Prostate Cancer: Results of a Case-Control Study Involving 201 Patients within a Population-Based Screening with a 4-Year Interval. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4391-4396.	3.6	42
102	IGF-I and Longevity. <i>Hormone Research in Paediatrics</i> , 2004, 62, 104-109.	1.8	20
103	A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. <i>Clinical Endocrinology</i> , 2004, 61, 195-203.	2.4	74
104	Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). <i>American Journal of Cardiology</i> , 2004, 94, 384-386.	1.6	37
105	The Influence of an Insulin-Like Growth Factor I Gene Promoter Polymorphism on Hip Bone Geometry and the Risk of Nonvertebral Fracture in the Elderly: The Rotterdam Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1280-1290.	2.8	64
106	There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 659-664.	3.3	8
107	Is there a role of ghrelin in preventing catabolism?. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 400-403.	3.3	10
108	Administration of Acylated Ghrelin Reduces Insulin Sensitivity, Whereas the Combination of Acylated Plus Unacylated Ghrelin Strongly Improves Insulin Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5035-5042.	3.6	224

#	ARTICLE	IF	CITATIONS
109	Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. American Journal of Medicine, 2004, 117, 158-162.	1.5	90
110	Identification of the <i>Bcl</i> polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids <i>in vivo</i> and body mass index. Clinical Endocrinology, 2003, 59, 585-592.	2.4	279
111	Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity. Journal of Endocrinological Investigation, 2003, 26, 588-594.	3.3	23
112	A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. European Journal of Endocrinology, 2003, 148, 171-175.	3.7	83
113	Endogenous Hormones and Carotid Atherosclerosis in Elderly Men. American Journal of Epidemiology, 2003, 157, 25-31.	3.4	221
114	Polymorphism in the Promoter Region of the Insulin-like Growth Factor I Gene Is Related to Carotid Intima-Media Thickness and Aortic Pulse Wave Velocity in Subjects With Hypertension. Stroke, 2003, 34, 1623-1627.	2.0	49
115	Central ghrelin production does not substantially contribute to systemic ghrelin concentrations: a study in two subjects with active acromegaly. European Journal of Endocrinology, 2002, 147, 195-199.	3.7	14
116	Ghrelin drives GH secretion during fasting in man. European Journal of Endocrinology, 2002, 146, 203-207.	3.7	135
117	A Polymorphism in the Glucocorticoid Receptor Gene, Which Decreases Sensitivity to Glucocorticoids In Vivo, Is Associated With Low Insulin and Cholesterol Levels. Diabetes, 2002, 51, 3128-3134.	0.6	294
118	The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?. European Journal of Endocrinology, 2002, 146, 467-477.	3.7	63
119	Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet, The, 2002, 359, 1036-1037.	13.7	191
120	Insulin-like growth factor-I genotype and birthweight. Lancet, The, 2002, 360, 945-946.	13.7	12
121	Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency. Clinical Endocrinology, 2002, 56, 765-771.	2.4	29
122	Commentary: A polymorphic CA repeat in the promoter region of the insulin-like growth factor I (IGF-I) gene. European Journal of Epidemiology, 2002, 18, 191-194.	5.7	10
123	Acute Stress Response in Children with Meningococcal Sepsis: Important Differences in the Growth Hormone/Insulin-Like Growth Factor I Axis between Nonsurvivors and Survivors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3118-3124.	3.6	26
124	Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-stimulated growth hormone secretion. Clinical Endocrinology, 2001, 55, 461-467.	2.4	12
125	A Polymorphism in the Gene for IGF-I. Diabetes, 2001, 50, 637-642.	0.6	338
126	Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. European Journal of Endocrinology, 2001, 145, 711-716.	3.7	105

#	ARTICLE	IF	CITATIONS
127	Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 478-481.	3.6	92
128	Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 478-481.	3.6	31
129	Blockade of the Growth Hormone (GH) Receptor Unmasks Rapid GH-Releasing Peptide-6-Mediated Tissue-Specific Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 590-593.	3.6	18
130	Acute Effect of Pegvisomant on Cardiovascular Risk Markers in Healthy Men: Implications for the Pathogenesis of Atherosclerosis in GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5165-5171.	3.6	2
131	Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clinical Endocrinology, 2000, 52, 1-9.	2.4	76
132	A Prospective Study on Circulating Insulin-Like Growth Factor I (IGF-I), IGF-Binding Proteins, and Cognitive Function in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4551-4555.	3.6	41
133	Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis?. Journal of Endocrinological Investigation, 1999, 22, 313-315.	3.3	32
134	Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. Clinical Endocrinology, 1998, 48, 471-478.	2.4	83
135	The acute effect of dexamethasone on plasma leptin concentrations and the relationships between fasting leptin, the IGF-I/IGFBP system, dehydroepiandrosterone, androstenedione and testosterone in an elderly population. Clinical Endocrinology, 1998, 48, 621-626.	2.4	26
136	Lack of associations between serum leptin, a polymorphism in the gene for the β 23-adrenergic receptor and glucose tolerance in the Dutch population.. Clinical Endocrinology, 1998, 49, 229-234.	2.4	26
137	The IGF-I/IGFBP system in congenital partial lipodystrophy. Clinical Endocrinology, 1998, 49, 465-473.	2.4	11
138	Insulin-like growth factor-I and risk of breast cancer. Lancet, The, 1998, 352, 490.	13.7	5
139	Insulin-like growth factor I receptors on blood cells: their relationship to circulating total and free IGF-I, IGFBP-1, IGFBP-3 and insulin levels in healthy subjects. Growth Hormone and IGF Research, 1998, 8, 47-54.	1.1	11
140	Serum Total IGF-I, Free IGF-I, and IGFBP-1 Levels in an Elderly Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 277-282.	2.4	223
141	Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. European Journal of Endocrinology, 1998, 138, 627-632.	3.7	56
142	Serum Free and Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 and Insulin-Like Growth Factor Binding Protein-3 Levels in Healthy Elderly Individuals. Gerontology, 1998, 44, 277-280.	2.8	30
143	Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 (IGFBP-1), and IGFBP-3 and Their Relationships to the Presence of Diabetic Retinopathy and Glomerular Hyperfiltration in Insulin-Dependent Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2809-2815.	3.6	55
144	IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clinical Endocrinology, 1995, 43, 501-505.	2.4	42

#	ARTICLE	IF	CITATIONS
145	Hemodynamic and Biochemical Effects of the AT 1 Receptor Antagonist Irbesartan in Hypertension. Hypertension, 1995, 25, 22-29.	2.7	97
146	Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.. Journal of Clinical Investigation, 1987, 79, 1635-1641.	8.2	365
147	Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGF1-R/INS-R antagonist OSI-906. Endocrine Abstracts, 0, , .	0.0	1
148	Efficacy and safety of switching to pasireotide LAR monotherapy or in combination with pegvisomant in acromegaly patients controlled with combination therapy of somatostatin analogues and pegvisomant (PAPE study): a prospective, open-label 48 week study. Endocrine Abstracts, 0, , .	0.0	0